Herpes Zoster Vaccine in Older Adults and the Risk of Subsequent Herpes Zoster Disease

被引:170
|
作者
Tseng, Hung Fu [1 ]
Smith, Ning [1 ]
Harpaz, Rafael [2 ]
Bialek, Stephanie R. [2 ]
Sy, Lina S. [1 ]
Jacobsen, Steven J. [1 ]
机构
[1] So Calif Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA
[2] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA
来源
关键词
INFLUENZA VACCINE; VARICELLA; EFFICACY; HOSPITALIZATIONS; EPIDEMIOLOGY; OPHTHALMICUS; MANAGEMENT; ACCURACY; CHILDREN; HISTORY;
D O I
10.1001/jama.2010.1983
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Approximately 1 million episodes of herpes zoster occur annually in the United States. Although prelicensure data provided evidence that herpes zoster vaccine works in a select study population under idealized circumstances, the vaccine needs to be evaluated in field conditions. Objective To evaluate risk of herpes zoster after receipt of herpes zoster vaccine among individuals in general practice settings. Design, Setting, and Participants A retrospective cohort study from January 1, 2007, through December 31, 2009, of individuals enrolled in the Kaiser Permanente Southern California health plan. Participants were immunocompetent community-dwelling adults aged 60 years or older. The 75 761 members in the vaccinated cohort were age matched (1:3) to 227 283 unvaccinated members. Main Outcome Measure Incidence of herpes zoster. Results Herpes zoster vaccine recipients were more likely to be white, women, with more outpatient visits, and fewer chronic diseases. The number of herpes zoster cases among vaccinated individuals was 828 in 130 415 person-years (6.4 per 1000 person-years; 95% confidence interval [CI], 5.9-6.8), and for unvaccinated individuals it was 4606 in 355 659 person-years (13.0 per 1000 person-years; 95% CI, 12.6-13.3). In adjusted analysis, vaccination was associated with a reduced risk of herpes zoster (hazard ratio [HR], 0.45; 95% CI, 0.42-0.48); this reduction occurred in all age strata and among individuals with chronic diseases. Risk of herpes zoster differed by vaccination status to a greater magnitude than the risk of unrelated acute medical conditions, suggesting results for herpes zoster were not due to bias. Ophthalmic herpes zoster (HR, 0.37; 95% CI, 0.23-0.61) and hospitalizations coded as herpes zoster (HR, 0.35; 95% CI, 0.24-0.51) were less likely among vaccine recipients. Conclusions Among immunocompetent community-dwelling adults aged 60 years or older, receipt of the herpes zoster vaccine was associated with a lower incidence of herpes zoster. The risk was reduced among all age strata and among individuals with chronic diseases. JAMA. 2011; 305(2): 160-166
引用
收藏
页码:160 / 166
页数:7
相关论文
共 50 条
  • [41] Herpes zoster vaccine in Korea
    Choi, Won Suk
    CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2013, 2 (02) : 92 - 96
  • [42] Herpes Zoster and Recurrent Herpes Zoster
    Shiraki, Kimiyasu
    Toyama, Nozomu
    Daikoku, Tohru
    Yajima, Misako
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (01):
  • [43] The herpes zoster subunit vaccine
    Cunningham, Anthony L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 265 - 271
  • [44] Herpes zoster virus vaccine
    Woolery, William Alan
    GERIATRICS-US, 2008, 63 (10): : 6 - 9
  • [45] A vaccine to prevent herpes zoster
    Kessler, KM
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13): : 1414 - 1414
  • [46] Herpes Zoster Vaccine Coverage in Older Adults in the US, 2007-2013
    Zhang, Dongmu
    Johnson, Kelly
    Newransky, Chrisann
    Acosta, Camilo J.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2017, 52 (01) : E17 - E23
  • [47] Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
    Le, Phuc
    Rothberg, Michael B.
    JAMA INTERNAL MEDICINE, 2018, 178 (02) : 248 - 258
  • [48] Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
    Cunningham, A. L.
    Lal, H.
    Kovac, M.
    Chlibek, R.
    Hwang, S. -J.
    Diez-Domingo, J.
    Godeaux, O.
    Levin, M. J.
    McElhaney, J. E.
    Puig-Barbera, J.
    Abeele, C. Vanden
    Vesikari, T.
    Watanabe, D.
    Zahaf, T.
    Ahonen, A.
    Athan, E.
    Barba-Gomez, J. F.
    Campora, L.
    de Looze, F.
    Downey, H. J.
    Ghesquiere, W.
    Gorfinkel, I.
    Korhonen, T.
    Leung, E.
    McNeil, S. A.
    Oostvogels, L.
    Rombo, L.
    Smetana, J.
    Weckx, L.
    Yeo, W.
    Heineman, T. C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1019 - 1032
  • [49] Efficacy of the Herpes Zoster Subunit Vaccine in Adults 65 Years of Age or Older
    McElhaney, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2018, 66 : S12 - S12
  • [50] Herpes Zoster Vaccine and the Incidence of Recurrent Herpes Zoster in an Immunocompetent Elderly Population
    Tseng, Hung Fu
    Chi, Margaret
    Smith, Ning
    Marcy, Stephen M.
    Sy, Lina S.
    Jacobsen, Steven J.
    JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (02): : 190 - 196